Table 6 Uni- and multivariate analysis of risk factors for graft loss or death

HSV-1 positivity (bile)

2.34 (0.70–7,80)

0.17

HSV-1 positivity (serum)

0.43 (0.06–3.49)

0.39

EBV positivity (bile)

0.82 (0.28–2.38)

0.72

EBV positivity (serum)

2.18 (0.47–10.02)

0.32

CMV positivity (bile)

0.21 (0.29–1.58)

0.13

HHV-6 positivity (bile)

2.72 (1.25–5.90)

0.01

2.15 (0.94–4.95)

0.07

HHV-6 positivity (liver biopsy)

1.02 (0.30–3.46)

0.98

HHV-7 positivity (bile)

2.57 (1.14–5.78)

0.02

2.03 (0.81–5.12)

0.13

Valganciclovir at time of ERC

1.78 (0.97–3.26)

0.07

0.99 (0.48–2.07)

0.87

Time between LT and ERC [months]

0.93 (0.86–1.01)

0.08

0.94 (0.79–1.12)

0.27

NAS vs. AS/control

1.74 (0.99–3.05)

0.05

0.94 (0.79–1.12)

0.47

Recipient age, years

1.02 (0.97–1.07)

0.49

Donor age, years

1.02 (0.99–1.04)

0.18

MELD score at LT

0.94 (0.81–1.01)

0.12

Cold ischemia time

0.96 (0.83–1.11)

0.39